{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:01:42Z","timestamp":1790683302337,"version":"4.1.0"},"reference-count":37,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022606","name":"Almirall","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023331","name":"LEO Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical &amp; Translational All"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dupilumab\u2010associated ocular surface disease (DAOSD) is the most reported side effect in dupilumab\u2010treated atopic dermatitis (AD) patients. We investigated the effect of long\u2010term dupilumab treatment on ocular surface disease (OSD), conjunctival goblet cells (GCs), and tear fluid dupilumab levels and proteins.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective study included moderate\u2010to\u2010severe AD patients at the University Medical Center Utrecht, the Netherlands. Patients initiating dupilumab between February 2020\u2013October 2022 were eligible to participate in scheduled ophthalmological examinations alongside routine dermatological examinations at baseline, week 28, and last follow\u2010up (\u2265 2\u00a0years). OSD severity was assessed using the Utrecht Ophthalmic Inflammatory and Allergic disease (UTOPIA) score, with DAOSD defined as a\u00a0\u2265 3\u2010point increase from baseline. Conjunctival GC quantity and function were assessed with impression cytology. Dupilumab levels and proteins were measured in tear fluid.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Forty\u2010four patients were included. OSD was present in 90.9% (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a040\/44) of patients at all visits. DAOSD occurred in 22.7% (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a010\/44) of patients; 40.0% (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a04\/10) persisted or newly developed at last follow\u2010up. Tear break\u2010up time decreased while tear production increased. Tear fluid dupilumab levels and AD\u2010related inflammatory proteins decreased over time. Conjunctival GCs decreased at last follow\u2010up compared to baseline. Mucin5AC (MUC5AC) production in CK19\u2010CD45\u2010MUC5AC\u00a0+\u00a0cells decreased at week 28 and remained stable at last follow\u2010up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>OSD remained common during long\u2010term dupilumab treatment in AD patients. Some patients developed worsening of OSD compatible with DAOSD, including delayed onset, highlighting the need for continued awareness of ocular side effects among clinicians. Reduced MUC5AC production and declining AD\u2010related inflammatory proteins in tear fluid suggest changes in conjunctival homeostasis and ocular inflammation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/clt2.70208","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:27:46Z","timestamp":1790681266000},"source":"Crossref","is-referenced-by-count":0,"title":["Long\u2010Term Ocular Outcomes of Dupilumab in Atopic Dermatitis: Results From the BioDay Registry"],"prefix":"10.1002","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9380-8003","authenticated-orcid":false,"given":"Nienke","family":"Veldhuis","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergology National Expertise Center for Atopic Dermatitis University Medical Center Utrecht  Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5617-8615","authenticated-orcid":false,"given":"Roselie E.","family":"Achten","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology National Expertise Center for Atopic Dermatitis University Medical Center Utrecht  Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal M.","family":"van Luijk","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology University Medical Center Utrecht  Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlot M.","family":"van der Wal","sequence":"additional","affiliation":[{"name":"Center for Translational Immunology University Medical Center Utrecht Utrecht University  Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance F.","family":"den Hartog Jager","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology National Expertise Center for Atopic Dermatitis University Medical Center Utrecht  Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaas P.\u00a0A.","family":"Zuithoff","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care University Medical Center Utrecht  Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsin","family":"El Amrani","sequence":"additional","affiliation":[{"name":"Division Laboratories, Pharmacy and Biomedical Genetics Department of Clinical Pharmacy University Medical Center Utrecht Utrecht University  Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7368-9820","authenticated-orcid":false,"given":"Edward F.","family":"Knol","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology National Expertise Center for Atopic Dermatitis University Medical Center Utrecht  Utrecht the Netherlands"},{"name":"Center for Translational Immunology University Medical Center Utrecht Utrecht University  Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke","family":"van Wijk","sequence":"additional","affiliation":[{"name":"Center for Translational Immunology University Medical Center Utrecht Utrecht University  Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9004-5111","authenticated-orcid":false,"given":"Marlies","family":"de Graaf","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology National Expertise Center for Atopic Dermatitis University Medical Center Utrecht  Utrecht the Netherlands"},{"name":"Department of Dermatology and Allergology Wilhelmina Children's Hospital University Medical Center Utrecht Utrecht University  Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M.","family":"Haeck","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology National Expertise Center for Atopic Dermatitis University Medical Center Utrecht  Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mor M.","family":"Dickman","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology University Medical Center Utrecht  Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1249-6993","authenticated-orcid":false,"given":"Marjolein S.","family":"de Bruin\u2010Weller","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology National Expertise Center for Atopic Dermatitis University Medical Center Utrecht  Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(20)31286\u20101"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.11.034"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.14461"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17869"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/ico.0000000000002866"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15717"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae344"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12386"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.70027"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ico.0000178741.14212.53"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.14127"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.1536"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257\u2010022\u201000685\u20100"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.09.042"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad159"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12221"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.14269"},{"key":"e_1_2_13_19_1","unstructured":"OPIA Technologies S.A.S. \u201cEYEPRIMTMHandbook \u201d [Internet] (2020) https:\/\/eyeprim.com\/shop\/wp-content\/uploads\/2020\/01\/Handbook-20200129-final.pdf."},{"key":"e_1_2_13_20_1","article-title":"Applied Longitudinal Analysis. Series in Probability and Statistics","author":"Fitzmaurice G. M.","year":"2011","journal-title":"John Wiley & Sons, Inc"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.04.026"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.07.074"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.03.003"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.11.037"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257\u2010019\u201000455\u20105"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2020.108115"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20706"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17538"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15326"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.9.3.29"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0161\u20106420(98)98032\u20100"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010012\u20100031\u2010y"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1542\u20100124(12)70149\u20100"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600\u20100420.2006.00699.x"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/icl.0b013e31822563be"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/ico.0b013e318158f6dc"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1076\/ceyr.22.1.8.6977"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.2517"}],"container-title":["Clinical and Translational Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clt2.70208","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/clt2.70208","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clt2.70208","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:27:48Z","timestamp":1790681268000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clt2.70208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/clt2.70208"],"URL":"https:\/\/doi.org\/10.1002\/clt2.70208","archive":["Portico"],"relation":{},"ISSN":["2045-7022","2045-7022"],"issn-type":[{"value":"2045-7022","type":"print"},{"value":"2045-7022","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"article-number":"e70208"}}